Product Description
Mechanisms of Action: Imaging Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Topical
FDA Designation: Fast Track - *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Photocure
Company Location: Europe
Company Founding Year: 1993
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Bladder Cancer|Transitional Cell Carcinoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2012-000559-15 |
FLUORESCENCE CYSTOSCOPY AND OPTIMIZED MMC IN RECURRENT BLADDER CANCER (FINNBLADDER 9) | P3 |
Completed |
Bladder Cancer|Transitional Cell Carcinoma |
2024-12-09 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/15/2025 |
News Article |
Photocure and Intelligent Scopes Corporation partner on development of AI for blue light cystoscopy |
|
08/28/2025 |
News Article |
Asieris Pharmaceuticals Releases 2025 Semi-Annual Report with Sustained Commercial Momentum and Breakthrough Innovation Poised for Launch |
|
03/26/2025 |
News Article |
Photocure appoints Jane Healy as Vice President and General Manager EMEA |
|
09/27/2024 |
News Article |
Photocure establishes Named Patient Program to provide access to Hexvix in South Africa |